CoChat

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

Open access
Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, Richardson, Paul · 2017 · British Journal of Haematology
Cited by 135

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: The randomized phase III ELOQUENT‐2 study (NCT 01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (EL d) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma. EL d reduced the risk of disease progression/death by 30% versus Ld (hazard ratio [HR] 0·70). Median time from diagnosis was 3·5 years. We present extended 3‐year follow‐up data. Endpoints included progression‐free survival (PFS), overall response rate (ORR) and interim overall survival (OS). Exploratory post‐hoc analyses included impact of time from diagnosis and prior lines of therapy on PFS, and serum M‐protein dynamic modelling. ORR was 79% (EL d) and 66% (Ld) (P = 0·0002). EL d reduced the risk of disease progression/death by 27% versus Ld (HR 0·73; P = 0·0014). Interim OS demonstrated a trend in favour of EL d (P = 0·0257); 1‐, 2‐ and 3‐year rates with EL d versus Ld were: 91% versus 83%, 73% versus 69% and 60% versus 53%. In patients with ≥ median time from diagnosis and one prior therapy, EL d resulted in a 53% reduction in the risk of progression/death versus Ld (HR 0·47). Serum M‐protein dynamic modelling showed slower tumour regrowth with EL d. Adverse events were comparable between arms. EL d provided a durable and clinically relevant improvement in efficacy, with minimal incremental toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.14787

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 5

  1. 10.1007/s00262-013-1493-8 · DOI · Paper page
  2. 10.1038/leu.2009.147 · DOI · Paper page
  3. 10.1158/1078-0432.CCR-07-4246 · DOI · Paper page
  4. 10.1038/clpt.2009.64 · DOI · Paper page
  5. 10.1158/1078-0432.CCR-09-1624 · DOI · Paper page

Cited by

See all 135

Metadata

Authors
Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Palumbo, A., San‐Miguel, J., Shpilberg, O., Anderson, K., Grosicki, S., Spicka, I., Walter‐Croneck, A., Magen, H., Mateos, M., Belch, A., Reece, D., Beksac, M., Bleickardt, E., Poulart, V., Sheng, J., Sy, O., Katz, J., Singhal, A., & Richardson, P.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2017-07-05
Volume
178
Issue
6
Pages
896-905
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2732548543
Cited by
135
References
4
FWCI
15.38
Type
journal article
Language
en
Open access
hybrid
Funders
Bristol-Myers Squibb in collaboration with AbbVie Biotherapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. https://app.cochat.ai/papers/10.1111/bjh.14787
The paper
Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Palumbo, A., San‐Miguel, J., Shpilberg, O., Anderson, K., Grosicki, S., Spicka, I., Walter‐Croneck, A., Magen, H., Mateos, M., Belch, A., Reece, D., Beksac, M., Bleickardt, E., Poulart, V., Sheng, J., . . . Richardson, P. (2017). Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. British Journal of Haematology. https://doi.org/10.1111/bjh.14787

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.